Catalent (NYSE:CTLT) Price Target Raised to $63.00

Catalent (NYSE:CTLT) had its target price boosted by Barclays from $47.00 to $63.00 in a research report report published on Friday morning, Benzinga reports. Barclays currently has an equal weight rating on the stock.

Several other equities analysts have also recently commented on the stock. Stephens reissued an equal weight rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. StockNews.com assumed coverage on shares of Catalent in a report on Saturday, June 22nd. They issued a sell rating on the stock. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of Hold and a consensus price target of $55.65.

Catalent Price Performance

Catalent stock opened at $56.17 on Friday. Catalent has a 52 week low of $31.80 and a 52 week high of $60.20. The company’s 50 day moving average price is $55.56 and its two-hundred day moving average price is $54.06. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37. The stock has a market cap of $10.17 billion, a P/E ratio of -9.21 and a beta of 1.16.

Catalent (NYSE:CTLT) last posted its earnings results on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The firm had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.11 billion. On average, equities analysts predict that Catalent will post -0.17 earnings per share for the current year.

Insider Buying and Selling at Catalent

In other Catalent news, insider Ricky Hopson sold 1,401 shares of the business’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total transaction of $76,018.26. Following the sale, the insider now owns 20,617 shares of the company’s stock, valued at approximately $1,118,678.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

Hedge funds and other institutional investors have recently bought and sold shares of the business. Lindbrook Capital LLC grew its position in shares of Catalent by 79.4% during the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after purchasing an additional 208 shares in the last quarter. Czech National Bank grew its position in shares of Catalent by 0.7% during the 1st quarter. Czech National Bank now owns 31,801 shares of the company’s stock valued at $1,795,000 after purchasing an additional 228 shares in the last quarter. BNP Paribas Asset Management Holding S.A. grew its position in shares of Catalent by 1.9% during the 4th quarter. BNP Paribas Asset Management Holding S.A. now owns 17,850 shares of the company’s stock valued at $802,000 after purchasing an additional 328 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. grew its position in shares of Catalent by 6.2% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,703 shares of the company’s stock valued at $256,000 after purchasing an additional 331 shares in the last quarter. Finally, Arizona State Retirement System grew its position in shares of Catalent by 0.7% during the 4th quarter. Arizona State Retirement System now owns 49,546 shares of the company’s stock valued at $2,226,000 after purchasing an additional 365 shares in the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.